NCI federally funded research and development center (FFRDC) contract.

Ended Awarded Last action

Contract number
75N91021F00002
Awardee
Awarding agency
Obligated
$6,289,947

Award facts

Opportunity
  • NCI210041 Solicitation number
Contract value 100% obligated
$6,289,947.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Frederick, MD 21702, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Terminate for Convenience P00010 -$81,137
Terminate for Convenience P00009 · EOI::implementing the presidents department of government efficiency cost efficiency initiative (march 19, 2025)::EOI $0
Other Administrative Action P00008 $0
Supplemental Agreement for work within scope P00007 · MOD 007 $111,099
Supplemental Agreement for work within scope P00006 $0
Supplemental Agreement for work within scope P00005 $0
Other Administrative Action P00004 $0
Other Administrative Action P00003 · This modification increases the task order value and extends the period of performance. $1,935,987
Other Administrative Action P00002 · This is no cost bilateral modification is to extend the period of performance $0
Other Administrative Action P00001 $0
Original award $4,323,998
Show all 11

About this award

This is a federal contract award to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., to serve as the National Cancer Institute's (NCI) Federally Funded Research and Development Center (FFRDC) contractor. The $6,289,947.00 cost-plus-fixed-fee contract, awarded on February 9, 2021, has a period of performance through November 13, 2025. Leidos Biomedical Research Inc. will provide a comprehensive range of biomedical research and facilities support services to the NCI, including operations and maintenance, research and development, clinical trials management, manufacturing, and specialized laboratory testing. This contract is not set aside for any particular business category. As the NCI's FFRDC contractor, Leidos Biomedical Research Inc. will support the institute's various research programs, including efforts related to cancer, infectious diseases, and therapeutics development.

Quick answers

Who was awarded contract 75N91021F00002?

75N91021F00002 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on February 9, 2021.

How much is contract 75N91021F00002 worth?

The government has obligated $6,289,947 on 75N91021F00002.

Is contract 75N91021F00002 an order under another contract?

Yes. 75N91021F00002 is a delivery order under 75N91019D00024, an indefinite delivery contract.

Was contract 75N91021F00002 competed?

The extent of competition for 75N91021F00002 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award